CYBIN INC.

HELP

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$10.3M

1 fund

Feb 17, 2026

$31.4M

1 fund

+206% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 14, 2025

SC 13GRA Capital Management7.7%Mar 25, 2024

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 3,840,500Value: $31.4M

# Signal Note: OrbiMed Initiates $31.4M Position in CYBIN OrbiMed's new 3.84M share position signals conviction in CYBIN's psilocybin-assisted therapy pipeline, particularly for treatment-resistant depression (TRD) where the company is advancing Phase 2b studies. The $31.4M stake from a top-tier healthcare investor with strong track record in early-stage biotech de-risks execution risk and may indicate positive interim data visibility or upcoming catalysts in 2024-2025. Watch for Phase 2b TRD readout timing and any expanded indications (PTSD, anxiety) as near-term value inflection points.

Eventide Asset ManagementNEW

More HELP Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RNA2 funds IRON2 funds ARGX2 funds PRAX2 funds ALNY2 funds AXSM2 funds EWTX2 funds DYN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Eventide Initiates CYBIN Position Eventide's $10.3M entry into CYBIN suggests conviction in the company's psychedelic-assisted therapy pipeline, particularly COMP360 (psilocybin) for treatment-resistant depression (TRD), which completed Phase 2b dosing in 2023. The values-aligned investor's entry may signal confidence in upcoming Phase 3 data readout and regulatory pathway clarity, though near-term catalysts and competitive positioning versus Compass Pathways (CMPS) warrant monitoring.